Michel Vounatsos, Biogen CEO (Dina Rudick/The Boston Globe via Getty Images)
Biogen loses another bid to revive Tecfidera patent as generic keeps eating into blockbuster sales
When Biogen lost its appeal to revive a key patent for Tecfidera last November, the big biotech filed for a rehearing in a last-ditch effort …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
